A reinspection in late 2016 was unable to lift the stigma. That visit resulted in 10 observations, some of which the FDA noted were repeats. The warning letter landed just months after Sun's $4 billion buyout of long-troubled Indian drugmaker Ranbaxy Laboratories, an acquisition that was expected to set Sun up as the dominant generics player in India and place it among the largest in the world. But instead of being able to build on that deal, Sun found itself investing time and millions of dollars on upgrades at Halol. It also had to look for contractors to produce some important generics that otherwise would have been manufactured at Halol. RELATED: Sun Pharma's 2019 revenues to fall short on U.S. generics price pressure as manufacturing issues persist The problems have weighed heavily on Sun's finances.